AffiliationCRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.
MetadataShow full item record
AbstractInterleukin-2 (IL-2) is a cytokine with potent immunomodulating properties which has shown considerable antitumour activity in preclinical models. In clinical trials, the effects of IL-2 given by various routes and schedules have been investigated. IL-2 has been administered either as single drug or in combination with other cytokines and immunomodulating agents, chemo therapeutic agents, or reinfusions of ex vivo activated autologous cytotoxic effector cells. The results of published clinical studies with IL-2 based immunotherapy are reviewed in this paper.
CitationClinical applications of interleukin-2. 1992, 4 (3):229-46 Prog Growth Factor Res
JournalProgress in Growth Factor Research
- Adoptive immunotherapy of urologic tumors.
- Authors: Belldegrun A, Rosenberg SA
- Issue date: 1989
- Therapy with interleukin-2 and tumor-derived activated lymphocytes.
- Authors: Oldham RK
- Issue date: 1994
- Prospects for gene therapy and lymphokine therapy for metastatic melanoma.
- Authors: Sivanandham M, Scoggin SD, Sperry RG, Wallack MK
- Issue date: 1992 Jan
- [Immunotherapy of malignant melanoma].
- Authors: Flageul B, Miclea JM, Bensussan A, Degos L
- Issue date: 1990 Oct
- [Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology].
- Authors: Barón Saura JM, Pizarro Redondo A, Berrocal Jaime A, González Barón M
- Issue date: 1991 May